Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 with adebrelimab with or without other antitumor therapy in recurrent/metastatic head and neck squamous cell carcinoma
CTR20252586Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102, adebrelimab, SHR-9839 in head and neck squamous cell carcinoma (HNSCC), sponsored by Hengrui Therapeutics. Started Jul 2025; status: active.
02
Drugs
SHR-A2102adebrelimabSHR-9839
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20252586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252586.